Navigation Links
Alzheimer's disease therapeutic prevents long-term damage from TBI in pre-clinical studies
Date:3/15/2009

WASHINGTON, D.C. A class of Alzheimer's disease drugs currently studied in clinical trials appears to reduce damage caused by traumatic brain injury in animals, researchers at Georgetown University Medical Center report in an upcoming advance online publication of Nature Medicine.

They say the results suggest that this class of drugs could potentially do something no other drug has been able to do-- prevent the long-term and continuing damage that often follows a serious injury to the brain.

That is because the agents, known as gamma secretase inhibitors, are designed to prevent build-up of amyloid, a toxic peptide found in the brain. This peptide clogs the brains of Alzheimer's patients but it is has also been found in people who have died from traumatic brain injury, says the study's lead author, neuroscientist Mark Burns, PhD, an assistant professor at GUMC.

"No one knows why it occurs, but abnormal amounts of amyloid plaque have been found during an autopsy in about a third of brain injury victims, some of whom were children who would ordinarily never have had these deposits," says Burns. "Remarkably, these deposits may occur in less than one day after injury."

There is another connection between traumatic brain injury and Alzheimer's disease, he says it is known that people who suffered a brain injury had a 400 percent increased risk of developing the disorder.

"But up until now, these were just interesting observations," Burns says. "In this study we show that the same pathways activated chronically in Alzheimer's disease are activated acutely in traumatic brain injury and that they appear to play a very important role in secondary injury."

Severe brain injury usually produces an immediate "necrotic" death of nerve cells, but this damage is often followed by a secondary wave of injury that can last weeks, months, and even years, Burns says. This damage comes from apoptosis, which is a different form of cell death, and can result in large holes in brain tissue that cause lasting neurological effects. To date, there has been no way to prevent or treat this damage, he says.

In this study, the investigators sought to understand if amyloid peptide contributed to secondary injury. Amyloid peptides are produced when a long protein in the brain known as the amyloid precursor protein (APP) is cut in two by the enzyme beta secretase, and then cut into smaller pieces by a second enzyme, known as gamma secretase.

The researchers went on to test Alzheimer's disease amyloid-busting agents as a brain injury treatment. It worked. "By using a gamma secretase inhibitor, we prevented much of secondary traumatic brain injury in mice in our experiments," he says.

To look at the role of amyloid in brain injury, the researchers used two different approaches to blocking activation of the pathway that produces amyloid peptide. They used a group of mice that were genetically altered so that they did not produce any beta secretase, which meant they were incapable of producing amyloid.

They also treated "normal" mice with the experimental agent DAPT, one of the first gamma secretase inhibitors developed and the model upon which some Alzheimer's disease drugs now in clinical testing are based. As a result, amyloid peptide production was substantially reduced in this group.

They first showed that in a group of normal control mice, brain injury produced substantially more amyloid peptide, and that the brain region known as the hippocampus, which is also affected in Alzheimer's disease, was substantially damaged.

They then followed the groups of reduced amyloid mice after injury, and found that three weeks after initial trauma, both groups performed almost equally well on learning tests. Magnetic resonance imaging scans of the mice showed that these two groups of mice did not have "nearly the same amount of damage in the hippocampus of their brain as control mice did," Burns says.

"The experiment with the genetically altered mice shows that amyloid peptide contributes to the secondary damage seen in traumatic brain injury," he says. "If injured mice that cannot develop amyloid demonstrate reduced signs of secondary trauma, that points to amyloid peptide as a cause of this continuing damage."

The study using DAPT then proved that in mice able to produce amyloid, a gamma secretase inhibitor reduced amyloid peptide production, and significantly improved learning, Burns says. "This is an exciting finding that we hope can be readily tested in patients with traumatic brain injury," he says.


'/>"/>

Contact: Karen Mallet
km463@georgetown.edu
215-514-9751
Georgetown University Medical Center
Source:Eurekalert

Related biology news :

1. Paradigm shift in Alzheimerss research: new treatments
2. Iron is involved in prion disease-associated neuronal demise
3. Seeing stem cells helps in fight against peripheral arterial disease
4. Metastatic bone disease patients can walk in Lazarus footsteps
5. Pitt researchers describe molecular 2-step leading to protein clumps of Huntingtons disease
6. Stem cell breakthrough gives new hope to sufferers of muscle-wasting diseases
7. Computer superpower strengthens attempts to combat common diseases
8. Cats eye diseases genetically linked to diseases in humans
9. New discovery paves the way for new diagnosis of serious lung disease
10. Addiction: Insights from Parkinsons disease
11. Portable kit may 1 day detect plant disease before disastrous outbreak
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/17/2016)... Market Watch: Primarily supported by ownership types; Private ... market is to witness a value of US$37.1 billion by ... Annual Growth Rate (CAGR) of 10.75% is foreseen from ... North America is not way behind ... at 9.56% respectively. Report Focus: The ...
(Date:11/15/2016)... , Nov 15, 2016 Research and ... Global Forecast to 2021" report to their offering. ... ... USD 16.18 Billion by 2021 from USD 6.21 Billion in 2016, ... Growth of the bioinformatics market is driven by the ...
(Date:6/22/2016)... , June 22, 2016  The American College of ... Trade Show Executive Magazine as one of the fastest-growing ... May 25-27 at the Bellagio in Las Vegas ... the highest percentage of growth in each of the following ... exhibiting companies and number of attendees. The 2015 ACMG Annual ...
Breaking Biology News(10 mins):
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... DuPont ... honored with the Breakthrough Solution of the Year Award from Platts Global Energy ... ester (FDME). The award was announced at the 18th Platts Global Energy Awards, ...
(Date:12/9/2016)... TORONTO , Dec. 9, 2016 /PRNewswire/ - Portage ... Securities Exchange: PBT.U), is pleased to announce that Biohaven ... New Haven, Connecticut (PRWEB) Dec ... "Company" or "Biohaven") announced today that the U.S. Food ... drug designation request covering its drug candidate BHV-0223, an ...
(Date:12/8/2016)... Dec. 8, 2016  OncoSec Medical Incorporated ("OncoSec") ... DNA-based intratumoral cancer immunotherapies, today announced financial results ... "We are delivering on our commitment to ... ImmunoPulse┬« IL-12. We are pleased with the early ... trial, and we are focused on advancing our ...
(Date:12/8/2016)... , Dec. 8, 2016 Eurofins announces the appointment of ... President of Eurofins Scientific Inc. (ESI). Mr. Murray ... proven professional and entrepreneurial experience in leading international business teams. As ... food testing market to uphold Eurofins, status as the global leader ... , ...
Breaking Biology Technology: